| Trial ID: | L1238 |
| Source ID: | NCT02314403
|
| Associated Drug: |
Belatacept
|
| Title: |
Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02314403/results
|
| Conditions: |
Kidney Failure, Chronic|Renal Insufficiency
|
| Interventions: |
DRUG: Belatacept|DRUG: ATG|DRUG: Rituximab|RADIATION: Total Body Irradiation|RADIATION: Thymic Irradiation|PROCEDURE: Combined Bone Marrow/Kidney Transplantation
|
| Outcome Measures: |
Primary: Number of Participants With Successful Withdrawal of Immunosuppression, The Primary Outcome is: The induction of transient mixed chimerism and renal allograft tolerance (24 consecutive months off of immunosuppression), 5 Years |
|
| Sponsor/Collaborators: |
Sponsor: Massachusetts General Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
2
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2015-02
|
| Completion Date: |
2021-07
|
| Results First Posted: |
2021-09-02
|
| Last Update Posted: |
2021-10-25
|
| Locations: |
Massachusetts General Hospital, Boston, Massachusetts, 02114, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02314403
|
